Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.
Axsome, FDA and migraine
February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...
1hon MSN
We recently published a list of 10 AI News and Ratings Too Important to Miss. In this article, we are going to take a look at ...
Allogene Therapeutics, Inc. ALLO announced that the FDA has cleared its investigational ... the average surprise being 172.72%. 7 Best Stocks for the Next 30 Days Just released: Experts distill ...
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo. The ...
The FDA review process is anticipated to be completed ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
Merck (MRK) announced the U.S. FDA has accepted for priority review a supplemental new drug application seeking approval of Welireg, Merck’s ...
Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria. Review of the applications is expected to by completed in Q4 2025, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback